Antony Currie and Robert Cyran explain why regulatory fiat and a nonprofit competitor set up by disgruntled U.S. hospitals are making life hard for makers of generic medicine. That’s why Novartis is selling its unit on the cheap – and why other such deals may follow.
from Reuters Video: Latest Videos US https://ift.tt/2Qc1Wow
No comments:
Post a Comment